Needed for a
Clinical Research Trial
If you undergo hemodialysis
treatments three times each week using a catheter, you may be eligible.
Ask your doctor today.
Patients using a catheter to receive
hemodialysis treatments may be at risk in getting a Catheter Related
Bloodstream Infection (CRBSI). Nearly 1 in every 10 hemodialysis
catheters becomes infected each month. As a result of the infection,
your physician may recommend additional medicine for treatment or
the removal of your catheter.
Access Technology is looking for volunteers who are 18 years of
age or older to participate in a study that will determine the
effect of an investigational new therapy called AAT-023 which may
prevent and reduce the number of catheter-related bloodstream infections.
The AAT-023 therapy will be injected into a patient’s catheter
(similar to Heparin) between dialysis treatments.
You may be eligible
if you are/have:
- 18 years old or older
- End stage renal disease (ESRD) requiring 3 hemodialysis
- A tunneled and cuffed chronic hemodialysis catheter
The study will last
6-12 months. As a participant in the study, you will receive the
study medication (AAT-023) or Heparin in your catheter after each
If you are interested in learning more or participating
in the study, please contact:
- Click here to download the original PDF of this